Abstract
Human T-lymphotropic virus type 1 (HTLV-1), the first known human retrovirus, induces various human diseases with a long latency period. The mechanism by which the virus causes diseases is still unknown. Studies indicate that viral replication is important at least for the development of HTLV-1 associated myelopathy, and therefore treatments based on our knowledge of human immunodeficiency virus type-1 (HIV-1) can be utilized to develop potent antiretroviral therapies targeting the replication enzymes reverse transcriptase, protease and integrase as well as the envelope glycoproteins. Furthermore, accessory gene products such as Tax and HBZ may also provide targets for chemotherapy. Treatment targeting these viral proteins may prevent the development of other HTLV-1-related diseases including adult Tcell leukemia, although such treatment may not be useful during the progression of the disease. This review describes the characteristics of HTLV-1 replication enzymes, envelope glycoproteins, and accessory proteins Tax and HBZ, and discusses the status of drug development strategies.
Keywords: HTLV-1, protease, reverse transcriptase, integrase, envelope glycoproteins, Tax, HBZ, antiretroviral therapies
Infectious Disorders - Drug Targets
Title: Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection
Volume: 9 Issue: 2
Author(s): Peter Boross, Peter Bagossi, Irene T. Weber and Jozsef Tozser
Affiliation:
Keywords: HTLV-1, protease, reverse transcriptase, integrase, envelope glycoproteins, Tax, HBZ, antiretroviral therapies
Abstract: Human T-lymphotropic virus type 1 (HTLV-1), the first known human retrovirus, induces various human diseases with a long latency period. The mechanism by which the virus causes diseases is still unknown. Studies indicate that viral replication is important at least for the development of HTLV-1 associated myelopathy, and therefore treatments based on our knowledge of human immunodeficiency virus type-1 (HIV-1) can be utilized to develop potent antiretroviral therapies targeting the replication enzymes reverse transcriptase, protease and integrase as well as the envelope glycoproteins. Furthermore, accessory gene products such as Tax and HBZ may also provide targets for chemotherapy. Treatment targeting these viral proteins may prevent the development of other HTLV-1-related diseases including adult Tcell leukemia, although such treatment may not be useful during the progression of the disease. This review describes the characteristics of HTLV-1 replication enzymes, envelope glycoproteins, and accessory proteins Tax and HBZ, and discusses the status of drug development strategies.
Export Options
About this article
Cite this article as:
Boross Peter, Bagossi Peter, Weber T. Irene and Tozser Jozsef, Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection, Infectious Disorders - Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/187152609787847686
DOI https://dx.doi.org/10.2174/187152609787847686 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Challenges in Diagnosis of Reproductive Dysfunction
Current Women`s Health Reviews Management of Early Stage Cervical Cancer
Reviews on Recent Clinical Trials Multifunctional Dendritic Drug Delivery Systems: Design, Synthesis, Controlled and Triggered Release
Current Topics in Medicinal Chemistry Presence of Intratumoral Stem Cells in Breast Cancer Patients with or without BRCA Germline Mutations
Current Cancer Drug Targets Evidence for a Putative Relationship Between Type 2 Diabetes and Neoplasia with Particular Reference to Breast Cancer: Role of Hormones, Growth Factors and Specific Receptors
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Good Practice in Umbilical Cord Blood Collection in Order to Identify Suitable Units Before Cryopreservation
Letters in Drug Design & Discovery Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry The PI3K/AKT/mTOR-Signal Transduction Pathway as Drug Target in Triple-Negative Breast Cancer
Clinical Cancer Drugs Current Research on Opioid Receptor Function
Current Drug Targets Management of Endometrial Cancer: A Review
Reviews on Recent Clinical Trials Patent Selections
Recent Patents on Biomarkers Current Scenario of Acridine Hybrids with Anticancer Potential
Current Topics in Medicinal Chemistry Fine Tuning Antibody Conjugation Methods using SNAP-tag Technology
Anti-Cancer Agents in Medicinal Chemistry Psychological Adjustment of Women in Cervical Cancer Screening
Current Women`s Health Reviews Innovative Roles for Surgical Robotics in Reproductive Surgery
Current Women`s Health Reviews Relationship Between Body Mass Index and Reproduction
Current Women`s Health Reviews